Scholl, Isabelle https://orcid.org/0000-0002-7639-0880
Hahlweg, Pola
Lindig, Anja
Bokemeyer, Carsten
Coym, Anja
Hanken, Henning
Müller, Volkmar
Smeets, Ralf
Witzel, Isabell
Kriston, Levente
Härter, Martin
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (232160533)
Article History
Received: 31 January 2018
Accepted: 12 March 2018
First Online: 27 March 2018
Ethics approval and consent to participate
: The study was approved by the Ethics Committee of the Medical Association Hamburg (Germany, study ID PV5368). The study will be carried out in accordance with the latest version of the Helsinki Declaration of the World Medical Association. Principles of good clinical practice will be respected. Data protection requirements will be met. For patients that are participating in data collection (i.e., audio recording of consultations, filling in SDM-Q-9), written consent will be obtained after information on aims of the study, data collection, and the use of collected data. Study participation is voluntary. A waiver of consent for HCPs was obtained from the ethics committee, as proposed by current statements on ethical designs of cluster randomized trials [] and implementation research []. All participating HCPs may decline to participate in the study.
: Not applicable.
: IS’s, PH’s, AL’s, LK’s, and MH’s institution receives the grant from the German Research Foundation for the study described in this study protocol (cp. funding). IS conducted one physician training in shared decision-making for which she received travel compensation from Mundipharma GmBH in 2015. MH declares that he is a co-PI in SDM training projects, one funded by the German Cancer Aid and one by Mundipharma. CB is the president of the German Society for Hematology and Oncology and receives support for clinical trials from several pharmaceutical companies (> 70 trails in his department) and holds grants, e.g., from the German Cancer Aid, Hubertus Wald Foundation and others. The authors did not receive industry funding for this paper, nor were pharmaceutical companies involved in any steps of the study or publication process. PH, AL, AC, HH, VM, RS, IW and LK declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.